Plasma β-endorphin levels in obese and non-obese patients with polycystic ovary disease

References

• Ferin M, Van Vugt D, Wardlaw S. The hypo-thalamic control of the menstrual cycle and the role of endogenous opioid peptides. Recent Prog Horm Res 1984;40:441–62
   PubMedGoogle Scholar
• Yen SSC, Quigley ME, Reid RL, et al. Neuro-endocrinology of opioid peptides and their role in the control of gonadotropin and prolactin secre-tion. Am J Obstet Gynecol 1985;152:485–93
   PubMed Web of Science ®Google Scholar
• Genazzani AR, Petraglia F. Opioid control of luteinizing hormone secretion in humans. J Steroid Biochem 1989;33:751–5
   PubMedGoogle Scholar
• Lobo RA. The role of neurotransmitters and opioids in polycystic ovarian syndrome. Endocrinol Metab Clin N Am 1988;17:667–704
   PubMedGoogle Scholar
• Petraglia F, D'Ambrogio G, Comitini G, et al. Impairment of opioid control of luteinizing hormone secretion in menstrual disorders. Fertil Steril 1985;43:535–40
   Web of Science ®Google Scholar
• Barnes RB, Lobo RA. Central opioid activity in polycystic ovary syndrome with and without dopa-minergic modulatio n. J Clin En docrinol Metab 1985; 61:779–82
   PubMed Web of Science ®Google Scholar
• Givens JR., Wiedeman E, Andersen RN, et al. I3-Endorphin and P-lipotropin plasma levels in hir-sute women: correlation with body weight. J Clin Endocrinol Metab 1980;50:975–6
   PubMed Web of Science ®Google Scholar
• Schoemaker J. Neuroendocrine control in poly-cystic ovary like syndrome. Gynecol Endocrinol 1991;5:277–88
   PubMed Web of Science ®Google Scholar
• Cumming DC, Reid RL, Quigley ME, et al. Evidence for decreased endogenous dopamine and opioid inhibitory influences on LH secretion in polycystic ovary syndrome. Clin Endocrinol 1984; 20:643–7
   PubMed Web of Science ®Google Scholar
• Berga SL, Yen SSC. Opioidergic regulation of LH pulsatility in women with polycystic ovary syndrome. Clin Endocrinol 1989;30:177–84
   PubMed Web of Science ®Google Scholar
• Desjardins GC, Beaudet A, Brawer JR. Alterations in opioid parameters in the hypothalamus of rats with estradiol induced polycystic ovary syndrome. Endocrinology 1990;127:2969–76
   Google Scholar
• Carmina E, Ditkoff E, Malizia G, et al. Increased circulating levels of immunoreactive I3-endorphin in polycystic ovary syndrome is not caused by increased pituitary secretion. Am J Obstet Gynecol 1992;167:1819–24
   PubMedGoogle Scholar
• Aleem FA, McIntosh T. Elevated plasma levels of 13-endorphin in a group of women with polycystic ovarian syndrome. Fertil Steril 1984;42:686–9
   PubMed Web of Science ®Google Scholar
• Wortsman J, Wehremberg WB, Gavin JR, et al. Elevated levels of plasma 13-endorphin and alpha 3 melanocyte stimulating hormone in polycystic ovary syndrome. Obstet Gynecol 1984;63:630–4
   PubMed Web of Science ®Google Scholar
• Nappi C, Petraglia F, Cudemo V, et al. Plasma 13-endorphin in obese and non-obese patients with polycystic ovarian disease. Eur J Obstet Gynecol Reprod Biol 1989;30:151–6
   PubMedGoogle Scholar
• Martinez-Guisasola J, Guerrero M, Alonso F, et al. The influence of the body weight to I3-endorphin plasma levels in a group of women with polycystic ovarian disease. Gynecol Endocrinol 1996;10 (suppl 4):232
   Google Scholar
• Martinez-Guisasola J, Ferrer J, Guerrero M, et al. Circulating levels of I3-immunoreactive I3-endorphin in polycystic ovary syndrome. Gynecol Endocrinol 1999;13: 26–35
   Google Scholar
• Margules DL, Moisset B, Lewis MJ, et al. I3-endorphin is associated with overeating in genetically obese mice (ob/ob) and rats (fa/fa). Science 1978;202:988–91
   PubMed Web of Science ®Google Scholar
• Rossier J, Rogers J, Shibasaki T, et al. Opioid peptides and melanocyte stimulating hormone in genetically obese (ob/ob) mice during develop-ment. Proc Nat Acad Sci 1979;76:2077–80
   PubMedGoogle Scholar
• Recant L, Voyles N, Wade A, et al. Studies on the role of opiate peptides in two forms of genetic obesity: ob/ob mouse and fa/fa rat. Horm Metabol Res 1983;15:589–93
   PubMedGoogle Scholar
• Yen SSC. The polycystic ovary syndrome. Clin Endocrinol 1980;12:177–207
   PubMedGoogle Scholar
• Barbieri RL, Hekris A, Ryan RJ. Effect of insulin on steroidogenesis in cultured porcine ovarian cells. Fertil Steril 1983;40:237–41
   Google Scholar
• Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syn-drome: an analysis of 263 consecutive cases. Clin Endocrinol 1990;32:213–20
   PubMed Web of Science ®Google Scholar
• Anttila L, Erkkola R, Ding Y-Q, et al. Clinical features and circulating gonadotropin, insulin and androgen interactions in women with polycystic ovarian disease. Fertil Steril 1991;55:1057–61
   Google Scholar
• Guilling-Smith C, Willis D, Beard RW, et al. Hypersecretion of androstenedione by isolated thecal cells from polycystic ovaries. J Clin Endocrinol Metab 1994;79:1158–65
   Google Scholar
• Peiris AN, Sothmann MS, Aiman EJ, et al. The relationship of insulin to sex hormone binding globulin levels in obese women with polycystic ovary syndrome: role of adiposity. Fertil Steril 1989;52:69–72
   PubMedGoogle Scholar
• Nestler JE, Powers LP, Matt DW, et al. A direct effect of hyperinsulinemia on serum sex hormone binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 1991;72:83–9
   PubMed Web of Science ®Google Scholar
• Bruni JF, Watkins WB, Yen SSC. I3-endorphin in the human pancreas. J Clin Endocrinol Metab 1979; 49:649–51
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Lanzone A, Cucinelli F, et al. Long term naltrexone treatment reduces the exagerated insulin secretion in patients with polycystic ovarian disease. Obstet Gynecol 1993;82:191–7
   PubMed Web of Science ®Google Scholar
• Fulghesu AM, Ciampelli M, Fortini A, et al. Effect of opioid blockade on insulin metabolism in poly-cystic ovarian disease. Hum Reprod 1995;10:2253–7
   PubMedGoogle Scholar
• Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 1997;20:1183–98
   PubMed Web of Science ®Google Scholar
• Tropeano G, Lucisano A, Liberale I, et al. Insulin, C-peptide, androgens and 3-endorphin response to oral glucose in patients with polycystic ovary syn-drome. J Clin Endocrinol Metab 1994;78:305–9
   PubMedGoogle Scholar
• Recant L, Voyles N, Luciano M, et al. Naltrexone reduces weight gain, alters 13-endorphin, and reduces insulin output from pancreatic islets of genetically obese mice. Peptides 1980;1:309–13
   PubMed Web of Science ®Google Scholar
• Bernstein L, Garzone PD, Rudy T, et al. Pain per-ception and serum 3-endorphin in trauma patients. Psychosomatics 1995;36:276–84
   PubMed Web of Science ®Google Scholar
• Facchinetti F, Livieri C, Petraglia F, et al. Dexa-methasone fails to suppress hyperendorphinaemia of obese children. Acta Endocrinol (Copenh) 1987; 116:90–4
   PubMedGoogle Scholar
• Wilkinson M, Brawer JR, Wilkinson DA. Gonadal-steroid induced modification of opiate binding sites in anterior hypothalamus offemale rat. Biol Reprod 1985;11:279–81
   Google Scholar
• Carriere PD, Faro okhi R, Brawer JR. The role of aberrant hypothalamic opiatergic function in generating polycystic ovaries in the rat. Can J Physiol Pharmacol 1989;67:896–901
   PubMedGoogle Scholar
• Krieger DT, Martin JB. Brain peptides. N Engl J Med 1981;304:876–85
   PubMed Web of Science ®Google Scholar
• Aleem FA, Eltabbakh GH, Omar RA, et al. Ovarian follicular fluid 13-endorphin levels in normal and polycystic ovaries. Am J Obstet Gynecol 1987;156:1197–200
   PubMedGoogle Scholar
• Lanzone A, Fulghesu AM, Andreani CL, et al. Insulin secretion in polycystic ovarian disease: effect of ovarian suppression by GnRH agonist. Hum Reprod 1990;5:143–9
   PubMedGoogle Scholar
• Laatikainen T, Antila L, Suikkari AM, et al. Effect of naloxone on plasma insulin, insulin-like growth factor I, and its binding protein 1 in patients with polycystic ovarian disease. Fertil Steril 1990;54: 434–7
   PubMedGoogle Scholar
• Giugliano D, Ceriello A, Salvatore T, et al. 13-endorphin infusion restores acute insulin response to glucose in type II diabetes mellitus. J Clin Endocrinol Metab 1987;64:944–8
   PubMedGoogle Scholar
• Givens JH, Kurtz BR, Kitabchi AE, et al. Reduc-tion of hyperinsulinemia and insulin resistance by opiate receptor blockade. J Clin Endocrinol Metab 1987;64:377–82
   PubMed Web of Science ®Google Scholar
• Lanzone A, Fulghesu AM, Fortini A, et al. Effect of opiate receptor blockade on the insulin response to oral glucose load in polycystic ovarian disease. Hum Reprod 1991;6:1043–9
   PubMed Web of Science ®Google Scholar
• Pas quali R, Antenucci D, Casimirri F, etal. Clinical and hormonal characteristics of obese amenorrheic hyperandrogenic women before and after weight loss. J Clin Endocrinol Metab 1989;68:173–9
   PubMedGoogle Scholar
• Singh A, Hamiltion-Fairley D, Koistinen R, et al. Effect of insulin-like growth factor type I (IGF I) and insulin on the secretion of sex hormone binding globulin and IGF I binding protein by human hepato me cells. J Endocrinol 1990;124: 1–3
   PubMed Web of Science ®Google Scholar